Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical pharmacokinetics of acyclovir.

Literature DB >> 6342900

Clinical pharmacokinetics of acyclovir.

O L Laskin.

Abstract

Entities: Chemical

Mesh：

Substances：
Acyclovir

Year: 1983 PMID： 6342900 DOI： 10.2165/00003088-198308030-00001

Source DB: PubMed Journal: Clin Pharmacokinet ISSN： 0312-5963 Impact factor: 6.447

× No keyword cloud information.

59 in total

1. Effect of renal failure on the pharmacokinetics of acyclovir.

Authors: O L Laskin; J A Longstreth; A Whelton; H C Krasny; R E Keeney; L Rocco; P S Lietman
Journal: Am J Med Date: 1982-07-20 Impact factor: 4.965

2. Lack of toxicity of acyclovir to granulocyte progenitor cells in vitro.

Authors: R W McGuffin; F M Shiota; J D Meyers
Journal: Antimicrob Agents Chemother Date: 1980-09 Impact factor: 5.191

3. Latent herpes simplex virus infections in sensory ganglia of hairless mice prevented by acycloguanosine.

Authors: R J Klein; A E Friedman-Kien; E DeStefano
Journal: Antimicrob Agents Chemother Date: 1979-05 Impact factor: 5.191

4. Acyclovir kinetics after intravenous infusion.

Authors: P de Miranda; R J Whitley; M R Blum; R E Keeney; N Barton; D M Cocchetto; S Good; G P Hemstreet; L E Kirk; D A Page; G B Elion
Journal: Clin Pharmacol Ther Date: 1979-12 Impact factor: 6.875

Review 5. Overview of acyclovir pharmacokinetic disposition in adults and children.

Authors: M R Blum; S H Liao; P de Miranda
Journal: Am J Med Date: 1982-07-20 Impact factor: 4.965

6. Mucocutaneous herpes simplex virus infections in immunocompromised patients. A model for evaluation of topical antiviral agents.

Authors: R Whitley; N Barton; E Collins; J Whelchel; A G Diethelm
Journal: Am J Med Date: 1982-07-20 Impact factor: 4.965

7. The activity in vitro against herpes virus of 9-(2-hydroxyethoxymethyl)guanine (acycloguanosine), a new antiviral agent.

Authors: P Collins; D J Bauer
Journal: J Antimicrob Chemother Date: 1979-07 Impact factor: 5.790

8. Treatment of herpes virus infections in immunocompromised patients with acyclovir by continuous intravenous infusion.

Authors: S A Spector; M Hintz; C Wyborny; J D Connor; R E Keeney; S Liao
Journal: Am J Med Date: 1982-07-20 Impact factor: 4.965

9. Pharmacokinetics of orally administered acyclovir in patients with herpes progenitalis.

Authors: R B Van Dyke; J D Connor; C Wyborny; M Hintz; R E Keeney
Journal: Am J Med Date: 1982-07-20 Impact factor: 4.965

10. Acyclovir prophylaxis of herpes-simplex-virus infections.

Authors: R Saral; W H Burns; O L Laskin; G W Santos; P S Lietman
Journal: N Engl J Med Date: 1981-07-09 Impact factor: 91.245

28 in total

1. Acyclovir-induced renal failure: course and risk factors.

Authors: M G Bianchetti; C Roduit; O H Oetliker
Journal: Pediatr Nephrol Date: 1991-03 Impact factor: 3.714

Review 2. Pharmacokinetics of newer drugs in patients with renal impairment (Part I).

Authors: J P Fillastre; E Singlas
Journal: Clin Pharmacokinet Date: 1991-04 Impact factor: 6.447

3. Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients.

Authors: C V Fletcher; J A Englund; C K Edelman; C R Gross; D L Dunn; H H Balfour
Journal: Antimicrob Agents Chemother Date: 1991-05 Impact factor: 5.191

4. Acyclovir clearance by CAVHD.

Authors: T Jones; C Alderman
Journal: Intensive Care Med Date: 1991 Impact factor: 17.440

5. Negative correlation of n-octanol/water partition coefficient and transport of some guanine derivatives through rat jejunum in vitro.

Authors: A Kristl; J J Tukker
Journal: Pharm Res Date: 1998-03 Impact factor: 4.200